Sudden Unexpected Death in Epilepsy: A Personalized Prediction Tool
Authors
Affiliations
Objective: To develop and validate a tool for individualized prediction of sudden unexpected death in epilepsy (SUDEP) risk, we reanalyzed data from 1 cohort and 3 case-control studies undertaken from 1980 through 2005.
Methods: We entered 1,273 epilepsy cases (287 SUDEP, 986 controls) and 22 clinical predictor variables into a Bayesian logistic regression model.
Results: Cross-validated individualized model predictions were superior to baseline models developed from only average population risk or from generalized tonic-clonic seizure frequency (pairwise difference in leave-one-subject-out expected log posterior density = 35.9, SEM ± 12.5, and 22.9, SEM ± 11.0, respectively). The mean cross-validated (95% bootstrap confidence interval) area under the receiver operating curve was 0.71 (0.68-0.74) for our model vs 0.38 (0.33-0.42) and 0.63 (0.59-0.67) for the baseline average and generalized tonic-clonic seizure frequency models, respectively. Model performance was weaker when applied to nonrepresented populations. Prognostic factors included generalized tonic-clonic and focal-onset seizure frequency, alcohol excess, younger age at epilepsy onset, and family history of epilepsy. Antiseizure medication adherence was associated with lower risk.
Conclusions: Even when generalized to unseen data, model predictions are more accurate than population-based estimates of SUDEP. Our tool can enable risk-based stratification for biomarker discovery and interventional trials. With further validation in unrepresented populations, it may be suitable for routine individualized clinical decision-making. Clinicians should consider assessment of multiple risk factors, and not focus only on the frequency of convulsions.
Sudden Unexpected Death in Epilepsy: Central Respiratory Chemoreception.
Dereli A, Apaire A, El Tahry R Int J Mol Sci. 2025; 26(4).
PMID: 40004062 PMC: 11855741. DOI: 10.3390/ijms26041598.
Kerr W, Suprun M, Kok N, Reddy A, McFarlane K, Kwan P Epilepsia. 2024; 66(2):407-416.
PMID: 39707877 PMC: 11827720. DOI: 10.1111/epi.18197.
Personalization of SUDEP risk: A survey of transient subclinical comorbid changes.
Simeone K, Martenz D, Iyer S, Booth C, Herr S, Matthews S Epilepsy Res. 2023; 199:107259.
PMID: 38086218 PMC: 11772091. DOI: 10.1016/j.eplepsyres.2023.107259.
Increasing challenges to trial recruitment and conduct over time.
Kerr W, Reddy A, Seo S, Kok N, Stacey W, Stern J Epilepsia. 2023; 64(10):2625-2634.
PMID: 37440282 PMC: 10592378. DOI: 10.1111/epi.17716.
Time-to-event clinical trial designs: Existing evidence and remaining concerns.
Kerr W, Auvin S, Van der Geyten S, Kenney C, Novak G, Fountain N Epilepsia. 2023; 64(7):1699-1708.
PMID: 37073881 PMC: 10524279. DOI: 10.1111/epi.17621.